An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * Exelixis’ CABOMETYX Showed Positive Results Treating NET in Recent Trial On May 30, Exelixis, Inc., announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo...
A precision-medicine protocol for treating acromegaly can slash healthcare costs by 22% while more than doubling a patient’s chances of reaching hormonal remission, according to an economic analysis of the ACROFAST clinical trial. “Cost-effectiveness of personalized medical treatment in acromegaly: a post hoc analysis of the ACROFAST study,” a Spanish study recently published in the...
Honored by both the Endocrine Society and the European Society of Endocrinology with the 2026 Transatlantic Alliance Award, Anna L. Gloyn, DPhil, FMedSci, has made significant contributions to endocrine research on both sides of the Atlantic. Endocrine News speaks with Gloyn about what this award means to her, how a friend in college helped determine...
A Q&A with Executive Editor Mark A. Newman about the exciting next step for the Endocrine Society’s flagship member magazine, Endocrine News. June will mark a historical milestone for Endocrine News magazine as it fully transitions to an online-only publication. The magazine’s Executive Editor, Mark A. Newman, has been leading the publication since 2013 and...
Medical researchers have identified a dangerous and deceptive trend in the illicit drug market after two nondiabetic patients were admitted to intensive care with life-threatening hypoglycemia following heroin use. The cases, occurring years apart but linked by the same rare clinical presentation, reveal that heroin supplies are being contaminated with glipizide, a potent prescription medication...
Patients with classic adrenal hyperplasia (CAH) may be able to reduce their glucocorticoid (GC) doses with crinecerfont, a first-in-class corticotropin-releasing factor type 1 receptor antagonist, according to two studies recently published in The Journal of Clinical Endocrinology & Metabolism. Neurocrine Biosciences, Inc. funded the studies, and the company is marketing crinecerfont as CRENESSITY®. The two papers...
Endocrine Society Advocacy Victories – Join Endocrine Society Advocacy Campaigns The Endocrine Society is an advocacy leader representing the interests of members to policymakers. During the past year we have had many advocacy victories including: We also have several ways for you to join us in advocacy: Endocrine Society Advocates for Access to Affordable Anti-Obesity...
Each May in the U.S. is National Osteoporosis Awareness and Prevention Month which is observed to raise awareness about osteoporosis as well as promote prevention and early detection. Bone health is one of the cornerstones of endocrine science and practice, so we felt that this was the perfect issue to highlight some of the recent...
Honored by both the Endocrine Society and the European Society of Endocrinology with the 2026 Transatlantic Alliance Award, Anna L. Gloyn, DPhil, FMedSci, has made significant contributions to endocrine research on both sides of the Atlantic. Endocrine News speaks with Gloyn about what this award means to her, how a friend in college helped determine...
